GC-MS Based Metabolic Profiling of Parkinson’s Disease with Glutathione S-transferase M1 and T1 Polymorphism in Tunisian Patients

Rebai, Amal; Reçber, Tuba; Nemutlu, Emirhan; Chbili, Chahra; Kurbanoğlu, Sevinç; Kır, Sedef; Amor, Sana Ben; Özkan, Síbel A.; Saguem, Saâd

doi:10.2174/1386207323666200428082815

Cited by 8 publications

(4 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The outcome of interest with the highest number of studies was the genetics of PD in Africa with 67 articles . Clinical characteristics/features were described in 65 , 14 reported epidemiology 14,[157][158][159][160][161][162][163][164][165][166][167][168][169] , 16 studies investigated environmental risk factors of PD 81,[170][171][172][173][174][175][176][177][178][179][180][181][182] , and 10 studies examined patient experiences and quality of life (QoL) [183][184][185][186][187][188][189][190][191][192] . Studies which examined management and access to care (6) 20,[193][194][195][196][197] and education and training (3) [198][199][200] wer...…”

Section: Resultsmentioning

confidence: 99%

“…These studies focused on three major categories of environmental risk factors including exposure to heavy metals, infections/comorbidities and gene-environment interaction. Three studies (from Tunisia and Egypt) investigated gene-environment interaction among Africans with PD, 81,174,177 four studies (from South Africa, Morocco and Nigeria) investigated exposure to pesticides, heavy metals (manganese ) 175,176,178 , and similar trace elements 172 . These studies showed a positive association of these risk factors in the development of PD, but most were small studies with plans for future large-scale studies.…”

Section: Environmental Risk Factors For Pdmentioning

confidence: 99%

See 1 more Smart Citation

The State of Play of Parkinson’s Disease in Africa: A Systematic Review and Point of View

Okunoye

Zewde

Azar

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: Parkinson's disease (PD) has become a global public health challenge as disability and death due to the disease are growing rapidly in comparison to other neurological disorders. There are no up-to-date comprehensive reviews on the epidemiology, environmental and genetic risk factors, phenotypic characterization, and patient-reported outcomes of PD in Africa. This data is crucial to understanding the current and future burden and suggesting actionable and/or researchable gaps aimed at improving disease outcomes. Methodology: We conducted a systematic literature search using the electronic databases of Cochrane Central Register of Controlled Trials (CCRT), EMBASE, Medline, PsychINFO, Web of Science, Cumulative Index to Nursing and Allied Health Literature (CINAHL), African Journals (AJOL) and other unpublished literature. We included all studies providing data on people with PD in Africa from the start of each database till February 2023. Studies were not restricted based on diagnostic criteria or language. Outcomes of interest were summarised based on epidemiology, genetics, environmental risk factors, clinical characteristics, patient-reported outcomes (experience and quality of life), disease management and outcomes, access to care, patient support, and healthcare workforce training. We also investigated collaboration between African countries (internal) and across continents/world regions (external) and journal impact factors. Results: A total of 4,855 articles were identified, of which 180 were included in this review. The majority were published from North Africa (mainly from Tunisia, and involved collaboration with investigators from France, the United Kingdom, and the United States of America). West Africa (Nigeria), Southern Africa (South Africa) and East Africa (mainly Tanzania) also had a relatively high number of publications. Methodological design varied across studies. Based on the pre-determined outcomes, articles identified were genetics (67), clinical features (65), environmental risk factors (16), epidemiology (14), patient experience and quality of life (10), management and access to care (5) and education and training (3). Conclusions: The main hubs of PD-related research output in Africa are the Northern, Western and Southern regions of Africa (although with limited involvement of countries within these regions). External collaboration (outside the continent) currently predominates. There are considerable actionable and researchable gaps across all outcomes of interest, with a dearth of published information on health workforce capacity building, disease management and access to care, patient and caregiver engagement, and quality of life of people with PD in Africa. We recommend strengthening existing and emerging intercontinental networks for research, education, training and policy formulation and funding, leveraging on more recent developments such as the International Parkinson's Disease Genomics Consortium-Africa (IPDGC-Africa), the International Parkinson and Movement Disorder Society Africa Section (MDS-AS), World Health Organisation (WHO) and initiatives with similar objectives.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Environmental Risk Factors For Pdmentioning

confidence: 99%

The State of Play of Parkinson’s Disease in Africa: A Systematic Review and Point of View

Okunoye

Zewde

Azar

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Nevertheless, although the mentioned metabolites are encouraging, there are some challenges to overcome. Rebai et al suggested that PD patients’ metabolomic profile might depend on glutathione S-transferase polymorphism [ 173 ]. Specifically, the glutathione S-transferase theta 1 positive group of patients exhibited increased plasmatic levels of several organic acids (e.g., citric acid) while exhibiting decreasing levels of proline and valine [ 173 ].…”

Section: Parkinson’s Diseasementioning

confidence: 99%

“…Rebai et al suggested that PD patients’ metabolomic profile might depend on glutathione S-transferase polymorphism [ 173 ]. Specifically, the glutathione S-transferase theta 1 positive group of patients exhibited increased plasmatic levels of several organic acids (e.g., citric acid) while exhibiting decreasing levels of proline and valine [ 173 ]. It has been also reported that PD patients showed differences between males and females in epidemiological and clinical characteristics, sensitivity to risk factors, response to treatments, and a concentration of metabolites, including amino acids [ 174 ].…”

Section: Parkinson’s Diseasementioning

confidence: 99%

Metabolomic Footprint of Disrupted Energetics and Amino Acid Metabolism in Neurodegenerative Diseases: Perspectives for Early Diagnosis and Monitoring of Therapy

et al. 2023

View full text Add to dashboard Cite

The prevalence of neurodegenerative diseases (NDs) is increasing due to the aging population and improved longevity. They are characterized by a range of pathological hallmarks, including protein aggregation, mitochondrial dysfunction, and oxidative stress. The aim of this review is to summarize the alterations in brain energy and amino acid metabolism in Alzheimer’s disease (AD), Parkinson’s disease (PD), and Huntington’s disease (HD). Based on our findings, we proposed a group of selected metabolites related to disturbed energy or mitochondrial metabolism as potential indicators or predictors of disease. We also discussed the hidden challenges of metabolomics studies in NDs and proposed future directions in this field. We concluded that biochemical parameters of brain energy metabolism disruption (obtained with metabolomics) may have potential application as a diagnostic tool for the diagnosis, prediction, and monitoring of the effectiveness of therapies for NDs. However, more studies are needed to determine the sensitivity of the proposed candidates. We suggested that the most valuable biomarkers for NDs studies could be groups of metabolites combined with other neuroimaging or molecular techniques. To attain clinically applicable results, the integration of metabolomics with other “omic” techniques might be required.

show abstract

Review of Metabolomics-Based Biomarker Research for Parkinson’s Disease

Fan

Yang

et al. 2021

Mol Neurobiol

View full text Add to dashboard Cite

GC-MS Based Metabolic Profiling of Parkinson’s Disease with Glutathione S-transferase M1 and T1 Polymorphism in Tunisian Patients

Cited by 8 publications

References 36 publications

The State of Play of Parkinson’s Disease in Africa: A Systematic Review and Point of View

The State of Play of Parkinson’s Disease in Africa: A Systematic Review and Point of View

Metabolomic Footprint of Disrupted Energetics and Amino Acid Metabolism in Neurodegenerative Diseases: Perspectives for Early Diagnosis and Monitoring of Therapy

Review of Metabolomics-Based Biomarker Research for Parkinson’s Disease

Contact Info

Product

Resources

About